Special Issue "Vascular Endothelial Growth Factor (VEGF) and VEGF Receptor Inhibitors in Health and Disease"
Deadline for manuscript submissions: 23 December 2023 | Viewed by 10229
Vascular endothelial growth factors (VEGF-A/B/C/D and placental growth factor (PlGF)) and their receptors (VEGFRs) and co-receptor neuropilins (NRPs) are the main pro-angiogenic and lymphangiogenic factors in mammals. Pharmaceuticals targeting the VEGF/VEGFR axis have been successfully used to treat several cancers and ocular diseases but have shown some limitations, in particular regarding their long-term efficiency and their route of administration. In addition to small molecule inhibitors of the intracellular tyrosine kinase domain of the VEGFRs, inhibitors of extracellular VEGF/VEGFR protein–protein interaction have been developed. Among these ligands of VEGFs and of their receptors, compound classes were initially dominated by antibodies and aptamers. Interestingly, recent research has expanded to smaller molecular entities with designed properties such as nanobodies, peptides, and peptidomimetics. Moreover, new formulations and composition of matters are now developed to improve the delivery of inhibitors, specifically through ocular barriers. The conjugation of VEGF/VEGFR inhibitors with other molecular entities for specific targeting and for combination therapy is also a promising new strategy.
In this Special Issue, we aim to present significant research results in the field of VEGF/VEGFR inhibition that highlight the most recent strategies and promising therapeutic molecules. These studies will help to anticipate and shape the future therapeutic opportunities provided by an efficient modulation of this key axis in angiogenesis.
Dr. Sylvain Broussy
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- vascular endothelial growth factors (VEGFs)
- vascular endothelial growth factor receptors (VEGFRs)
- placental growth factor (PlGF)
- protein–protein interaction inhibitors
- small molecules
- targeted delivery